CoChat

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

Open access
Cho, Byoung Chul, Daste, Amaury, Ravaud, Alain, Salas, Sébastien, Isambert, Nicolas, McClay, Edward, Awada, Ahmad, Borel, Christian, Ojalvo, Laureen S, Helwig, Christoph, Rolfe, P Alexander, Gulley, James L, Penel, Nicolas · 2020 · Journal for ImmunoTherapy of Cancer
Cited by 90

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: We report the clinical activity and safety of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β)RII receptor (a TGF-β ‘trap’) fused to a human IgG1 monoclonal antibody blocking programmed death-ligand 1 (PD-L1), in patients with heavily pretreated squamous cell carcinoma of the head and neck (SCCHN). Methods: In this phase I dose-expansion cohort, patients with advanced SCCHN not amenable to curative therapy that progressed/recurred after platinum therapy in the recurrent/metastatic setting, or <6 months after platinum therapy in the locally advanced setting, received bintrafusp alfa 1200 mg intravenously every 2 weeks. The primary endpoint was confirmed best overall response (BOR; Response Evaluation Criteria for Solid Tumors (RECIST) 1.1) per independent review committee (IRC); other endpoints included BOR per investigator and safety. Results: As of August 24, 2018, 32 patients had received bintrafusp alfa (median follow-up 86.4 weeks; range 2–97). Per IRC, the confirmed objective response rate (ORR) was 13% (95% CI 4% to 29%; 4 partial responses (PR)); 4 patients had stable disease (SD) (disease control rate 34%; 95% CI 19% to 53%). Per investigator, there were 5 PRs (ORR, 16%), including 2 patients who developed delayed PRs after initial disease increase (total clinical response rate 22%). Responses (ORRs) were observed in patients with PD-L1-positive (12%), PD-L1-negative (17%; 73-10 antibody for immunohistochemistry), human papillomavirus (HPV)-positive (33%) and HPV-negative tumors (5%). Grade 3 treatment-related adverse events (TRAEs) were reported in 11 patients (34%), with no grade 4 TRAEs or treatment-related deaths. Conclusions: Bintrafusp alfa showed clinical activity across subgroups of PD-L1 expression and in HPV-positive tumors and had a manageable safety profile in patients with heavily pretreated advanced SCCHN. Activity in HPV-positive tumors is favorable compared with historical data from PD-L1 inhibitors and is being further investigated in an ongoing study of HPV-associated tumors. Trial registration number: NCT02517398.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000664

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 29

  1. 10.1002/ijc.29210 · DOI · Paper page
  2. 10.1093/aje/kwp222 · DOI · Paper page
  3. 10.1200/JCO.2015.61.6995 · DOI · Paper page
  4. Chow, 2016, Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort, J Clin Oncol, 34, 3838, 10.1200/JCO.2016.68.1478 · DOI · Paper page
  5. 10.1056/NEJMoa0802656 · DOI · Paper page
  6. 10.1016/S0140-6736(18)31999-8 · DOI · Paper page
  7. Grégoire, 2010, Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21 Suppl 5, v184, 10.1093/annonc/mdq185 · DOI · Paper page
  8. 10.1016/S1470-2045(15)70124-5 · DOI · Paper page
  9. Kushwaha, 2015, Gefitinib, methotrexate and methotrexate plus 5-fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma, Cancer Biol Ther, 16, 346, 10.4161/15384047.2014.961881 · DOI
  10. 10.1200/JCO.2006.06.7447 · DOI · Paper page
  11. 10.1200/JCO.2005.07.119 · DOI · Paper page
  12. 10.1200/JCO.2005.05.3348 · DOI · Paper page
  13. 10.1158/1078-0432.CCR-14-1756 · DOI
  14. 10.1016/S0140-6736(00)90011-0 · DOI · Paper page
  15. 10.1200/JCO.2016.70.1524 · DOI · Paper page
  16. 10.1158/1078-0432.CCR-07-1157 · DOI · Paper page
  17. Gilbert, 2015, A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma, Oral Oncol, 51, 376, 10.1016/j.oraloncology.2014.12.011 · doi:10.1016/j.oraloncology.2014.12.011
  18. 10.1158/1078-0432.CCR-09-2877 · DOI
  19. 10.1158/1078-0432.CCR-17-1904 · doi:10.1158/1078-0432.ccr-17-1904
  20. 10.1158/0008-5472.CAN-14-0602-T · DOI
  21. 10.1634/theoncologist.2016-0433 · DOI
  22. 10.1126/scitranslmed.aan5488 · DOI · Paper page
  23. Strauss, 2018, Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers, JCO, 36, 10.1200/JCO.2018.36.15_suppl.3007 · DOI
  24. Vugmeyster, 2018, Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1, JCO, 36, 10.1200/JCO.2018.36.15_suppl.2566 · doi:10.1200/jco.2018.36.15_suppl.2566
  25. 10.1038/nmeth.1923 · DOI · Paper page
  26. 10.1186/1471-2105-12-323 · DOI · Paper page
  27. Shankaran, 2015, Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475), Journal of Clinical Oncology, 33, 10.1200/jco.2015.33.15_suppl.3026 · DOI
  28. 10.1038/s41416-018-0131-9 · DOI · Paper page
  29. 10.1158/1078-0432.CCR-18-3944 · DOI · Paper page

Cited by

See all 90

Metadata

Authors
Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L. S., Helwig, C., Rolfe, P. A., Gulley, J. L., & Penel, N.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-07
Volume
8
Issue
2
Pages
e000664
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3038704019
Cited by
90
References
9
FWCI
3.77
Type
journal article
Language
en
Open access
gold
Funders
  • GlaxoSmithKline
  • Merck KGaA, Darmstadt, Germany

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. https://app.cochat.ai/papers/10.1136/jitc-2020-000664
The paper
Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L. S., Helwig, C., Rolfe, P. A., Gulley, J. L., & Penel, N. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000664

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.